Genentech Enspryng cuts MOGAD relapse risk 68%
See more from StockTitan in Google Search and AI answers.
Adds StockTitan as…
Roche gets FDA Priority Review for Enspryng TED
Roche (OTCQX:RHHBY) received FDA Priority Review for a supplemental Biologics License Application for…
Another setback for Enspryng as Roche halts Duchenne development
Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD). But…
Enspryng falls short of Roche’s expectations in myasthenia gravis
Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is…
Roche’s Enspryng cuts MOGAD relapse risk by 68% in phase 3
The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over,…
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
F. Hoffmann-La Roche Ltd Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein…
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is…
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
F. Hoffmann-La Roche Ltd Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein…
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
F. Hoffmann-La Roche Ltd Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein…
Roche ENSPRYNG cuts MOGAD relapse risk 68%
Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk…